Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF -mutant metastatic melanoma: a real-world propensity score–matched survival analysis
JNCI: Journal of the National Cancer Institute · 2026
DOI: 10.1093/jnci/djaf263 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2026. Verfasst von Yago Garitaonaindia und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev 2730, Denmark. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins B-raf, Antineoplastic Combined Chemotherapy Protocols, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: DAMMED, Novartis, Pierre Fabre.
Abstract (Originalsprache)
Background
Encorafenib is a BRAF inhibitor with a pharmacodynamic profile distinct from that of dabrafenib, including a longer dissociation half-life that may enable more sustained BRAF inhibition. It has been hypothesized that this could translate into superior clinical efficacy. We aimed to determine whether encorafenib plus binimetinib is superior to dabrafenib plus trametinib in terms of clinical activity and outcomes.
Methods
Patients were identified through the Danish Metastatic Melanoma Database, a national registry collecting prospective data on systemic treatments. We retrospectively retrieved baseline, treatment, and outcome data for patients with metastatic BRAF-mutant melanoma treated with encorafenib plus binimetinib or dabrafenib plus trametinib from 2017 to 2024. Both unmatched and propensity score–matched analyses were conducted to mitigate potential confounding.
Results
A total of 751 patients were included (422 dabrafenib plus trametinib, 329 encorafenib plus binimetinib). Baseline characteristics were balanced between groups. In the unmatched cohort, no statistically differences were observed between dabrafenib plus trametinib and encorafenib plus binimetinib in progression-free survival (PFS; median = 7.9 vs 8.0 months; hazard ratio [HR] = 0.99, P = .90), overall survival (median = 15.5 vs 15.4 months; HR = 0.91, P = .30), or melanoma-specific survival (median = 16.2 vs 15.7 months; HR = 0.94, P = .50). Propensity score–matched analyses confirmed these findings (PFS: HR = 1.05, P = .60; overall survival: HR = 0.922, P = .41; melanoma-specific survival: HR = 0.97, P = .74). Post hoc power analysis for detecting a 3-month survival difference was adequate for PFS (97.5%) but limited for overall survival (56.3%) and melanoma-specific survival (52.1%).
Conclusions
We found no evidence that encorafenib plus binimetinib is superior to dabrafenib plus trametinib in metastatic melanoma. These findings suggest that the choice between these combinations should be guided by tolerability profiles and economic considerations rather than efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev 2730, Denmark.
- Department of Oncology, Aarhus University Hospital, Aarhus 8200, Denmark.
- Department of Oncology, Odense University Hospital, Odense 5000, Denmark.
- Department of Oncology, Aalborg University Hospital, Aalborg 9000, Denmark.
ORCID-Profile: Yago Garitaonaindia, Rasmus Friis, Søren Kjær, Troels H Borch, Christina Ruhlmann, Henrik Schmidt, Lars Bastholt, Inge Marie Svane, Marco Donia, Eva Ellebaek
Förderung
- DAMMED
- Novartis
- Pierre Fabre
Zitieren
APA
Garitaonaindia, Y., Khan, S., Friis, R., Kjær, S., Borch, T. H., Ruhlmann, C., Guldbrandt, L. M., Luczak, A. A., Schmidt, H., Bastholt, L., Svane, I. M., Donia, M., & Ellebaek, E. (2026). Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF -mutant metastatic melanoma: a real-world propensity score–matched survival analysis. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf263
Vancouver
Garitaonaindia Y, Khan S, Friis R, Kjær S, Borch TH, Ruhlmann C, et al. Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF -mutant metastatic melanoma: a real-world propensity score–matched survival analysis. JNCI: Journal of the National Cancer Institute. 2026. doi:10.1093/jnci/djaf263
BibTeX
@article{Garitaonaindia2026,
author = {Garitaonaindia, Yago and Khan, Shawez and Friis, Rasmus and Kjær, Søren and Borch, Troels H and Ruhlmann, Christina and Guldbrandt, Louise M and Luczak, Adam A and Schmidt, Henrik and Bastholt, Lars and Svane, Inge Marie and Donia, Marco and Ellebaek, Eva},
title = {Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF -mutant metastatic melanoma: a real-world propensity score–matched survival analysis},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2026},
doi = {10.1093/jnci/djaf263}
}
EUVIMED